The Food and Drug Administration on Wednesday approved a one-time treatment for lymphoma in adults, only the second time a gene therapy for blood cancer has been given the okay in the United States.
This is the first gene therapy approved for adults, and it involves removing a patient's T cells, reprogramming them to find and kill cancer cells, then putting the cells back into the patient, The Associated Press reports. The treatment uses the same technology as a gene therapy recently approved in the U.S. for childhood leukemia, and will cost $373,000 per patient, its manufacturer said.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.